Liaoning Chengda Biotechnology Co.,Ltd. (688739.SS) has a MoatMap StockRank of 44/100 based on Quality (59/100), Value (27/100), and Momentum (45/100) factor scores. The current signal is HOLD. Liaoning Chengda Biotechnology is a vaccine manufacturer facing domestic pricing pressure and lacks the global scale or CDMO pricing power required for our portfolio.
Liaoning Chengda Biotechnology Co., Ltd. is a leading biopharmaceutical company specializing in the development and manufacture of vaccines for human use, most notably its flagship rabies vaccine. The company is the largest producer of human rabies vaccines in China, utilizing advanced bioreactor cell culture technology to ensure high quality and yield. Its established brand reputation and extensive domestic and international distribution networks form a highly defensive competitive moat.
| Price | $2.98 |
| Market Cap | $1.3B |
| P/E (TTM) | 149.43 |
| P/E (Forward) | 38.74 |
| Price/Book | 0.92 |
| Return on Equity | 0.6% |
| Return on Invested Capital | 1.8% |
| Debt/Equity | 0.10 |
| Gross Margin | 70.1% |
| Operating Margin | -0.7% |
| Revenue Growth | -23.7% |
| Dividend Yield | 0.5% |
| Free Cash Flow | $-4M |
Liaoning Chengda Biotechnology Co.,Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).